ストックスクリーナーアプリを入手
5.80
4.92%
-0.30
前日終値:
$6.10
開ける：
$6.04
24時間の取引高:
1.86M
Relative Volume:
0.72
時価総額：
$509.67M
収益：
$30.91M
当期純損益:
$-209.47M
株価収益率:
-1.7428
EPS:
-3.3279
ネットキャッシュフロー:
$-147.13M
1週間 パフォーマンス:
-4.13%
1か月 パフォーマンス:
+51.83%
6か月 パフォーマンス:
-4.92%
1年 パフォーマンス:
-6.30%
1日の値動き範囲:
$5.54
$6.09
1週間の範囲:
$5.54
$6.4643
52週間の値動き範囲:
$3.43
$11.24
Verastem Inc Stock (VSTM) Company Profile
Compare VSTM vs VRTX, REGN, ARGX, RVMD, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
VSTM
Verastem Inc
|
5.80 | 534.27M | 30.91M | -209.47M | -147.13M | -3.3279 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Verastem Inc Stock (VSTM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-03-12 | 再開されました | BTIG Research | Buy |
| 2026-02-04 | 開始されました | H.C. Wainwright | Buy |
| 2025-10-16 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-04-10 | 開始されました | Jefferies | Buy |
| 2025-03-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-12-31 | 繰り返されました | BTIG Research | Buy |
| 2024-09-30 | 開始されました | Guggenheim | Buy |
| 2023-11-21 | 再開されました | BTIG Research | Buy |
| 2023-09-27 | 開始されました | B. Riley Securities | Buy |
| 2023-06-15 | アップグレード | Mizuho | Neutral → Buy |
| 2022-09-07 | 再開されました | Alliance Global Partners | Buy |
| 2022-04-29 | 再開されました | Cantor Fitzgerald | Overweight |
| 2022-04-14 | 開始されました | RBC Capital Mkts | Outperform |
| 2022-03-09 | 開始されました | Truist | Buy |
| 2021-07-01 | 開始されました | Alliance Global Partners | Buy |
| 2021-05-24 | アップグレード | BTIG Research | Neutral → Buy |
| 2019-06-20 | ダウングレード | BTIG Research | Buy → Neutral |
| 2019-05-10 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2018-07-13 | 開始されました | BTIG Research | Buy |
| 2018-05-02 | 開始されました | Seaport Global Securities | Buy |
| 2018-03-08 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-09-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2017-04-13 | 開始されました | Oppenheimer | Outperform |
| 2017-03-24 | 繰り返されました | H.C. Wainwright | Buy |
| 2015-09-29 | ダウングレード | Cantor Fitzgerald | Buy → Hold |
| 2015-09-29 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
| 2015-09-29 | ダウングレード | Jefferies | Buy → Hold |
| 2015-09-29 | ダウングレード | Raymond James | Strong Buy → Outperform |
| 2015-09-28 | ダウングレード | Mizuho | Buy → Neutral |
| 2015-09-28 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2015-09-09 | 開始されました | Raymond James | Strong Buy |
| 2015-05-12 | 繰り返されました | UBS | Buy |
| 2015-04-08 | 開始されました | H.C. Wainwright | Buy |
| 2015-01-23 | 繰り返されました | ROTH Capital | Buy |
| 2014-07-08 | 再開されました | Oppenheimer | Perform |
| 2014-02-11 | 開始されました | Mizuho | Buy |
すべてを表示
Verastem Inc (VSTM) 最新ニュース
Verastem Inc (VSTM) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Verastem Inc (VSTM) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Verastem Inc (VSTM) Balance Sheet - TradingKey
Verastem Inc (VSTM) Valuation: PE, PB & Fair Value Analysis - TradingKey
Verastem Inc (VSTM) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Verastem Inc (VSTM) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Verastem Inc (VSTM) Income Statement - TradingKey
VSTM|Verastem Inc|Price:6.085|Chg%:+0.035 - TradingKey
Verastem Inc (VSTM) Cash Flow - TradingKey
Verastem Inc (VSTM) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Verastem, Inc. Revenue Breakdown – HAM:2VSA - TradingView
VSTM|Verastem Inc|Price:6.050|Chg%:-0.130 - TradingKey
Verastem Inc. (VSTM) holder outlines potential sale of 31,924 common shares - Stock Titan
Verastem Oncology to report Q2 2026 results on Aug 6 - scanx.trade
Press Release: Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 - Moomoo
Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026 - Business Wire
Verastem Oncology to report Q2 2026 financial results in conference call - Bitget
Verastem (VSTM) Launches TARGET-D 202 Trial for KRAS G12D Lung C - GuruFocus
Phase 2 clinical trial for KRAS G12D-mutated lung cancer treatment begins at Verastem, Inc. - Traders Union
Verastem doses first patient in lung cancer trial for VS-7375 - Investing.com Canada
Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer - Business Wire
Verastem Inc (VSTM) Q1 2026 Earnings ReportResults, Call & Slides - TipRanks
These 7 Small Caps Are on Fire as the Second Half Begins: Here’s Why - Sahm
Verastem Inc. (VSTM) Posts Modest Gain as Biotech Sector Sees Renewed InterestIPO Entry Watch - dars.gov.et
Verastem’s KRAS G12D Trial Targets a New Niche in Colorectal Cancer - TipRanks
RBC Capital Reaffirms Outperform Rating For Verastem (VSTM) - Yahoo Finance
Polar Capital Holdings Plc Reduces Stake in Verastem Inc: A Stra - GuruFocus
Trading the Move, Not the Narrative: (VSTM) Edition - Stock Traders Daily
Verastem Inc. (VSTM) Q1 2026 Earnings: Narrower-Than-Expected Loss Supports Investor SentimentOne-Time Gain Impact - DonanımHaber
Verastem (VSTM) Surges 6.3%: Is This an Indication of Further Gains? - Yahoo Finance
Verastem Inc. (VSTM) Dips 5% as Biotech Volatility Persists – Technical Levels in FocusAndrews Pitchfork - dars.gov.et
Polar Capital group files 13G/A reporting 3.7M shares in Verastem (VSTM) - Stock Titan
Verastem Inc outlines oncology focus as investors weigh long-term prospects - ad-hoc-news.de
RBC Capital Maintains Verastem(VSTM.US) With Buy Rating, Cuts Target Price to $14 - Moomoo
RBC Capital Adjusts Verastem Price Target to $14 From $15, Maintains Outperform Rating - marketscreener.com
Here’s What RBC Capital Has to Say About Verastem (VSTM) - Insider Monkey
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
(VSTM) Volatility Zones as Tactical Triggers - Stock Traders Daily
VSTM Maintained by BTIG -- Price Target Unchanged at $18.00 - GuruFocus
Verastem Price Target Maintained With a $18.00/Share by BTIG - Moomoo
Verastem Oncology grants inducement awards to 31 new employees - scanx.trade
Enterprise value to EBIT forward of Verastem, Inc. – NASDAQ:VSTM - TradingView
Verastem (VSTM) Shares Encouraging Results from VS-7375 Phase 1/2 Trial - Insider Monkey
5 Best Stocks Under $10 Offering More Than 50% Upside - Insider Monkey
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell Small Cap Comp Value Benchmark - marketscreener.com
Verastem Inc at RBC Capital Markets Global Healthcare Conference Transcript - GuruFocus
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 3000 Value Benchmark - marketscreener.com
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell 2000 Value Benchmark - marketscreener.com
Verastem, Inc.(NasdaqCM: VSTM) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Why Did Verastem Stock Jump After-Hours Despite An Earnings Miss? - Stocktwits
Verastem, Inc. Actuals & Estimates (SWB:2VSA) - TradingView
Verastem Inc (VSTM) 財務データ
収益
当期純利益
現金流量
EPS
2.44%
0.02%
大文字化:
|
ボリューム (24 時間):